Lilly Signs US$870 M Licensing Pact with Camurus for Long-Acting FluidCrystal® Incretins
By Naini Anand
Pharma Deals Review: Vol 2025 Issue 6 (Table of Contents)
Published: 23 Jun-2025
DOI: 10.3833/pdr.v2025.i6.2955 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Lilly and Camurus have entered into a global collaboration and license agreement, granting Lilly exclusive rights to develop, manufacture, and commercialise long-acting incretin therapies using Camurus’ FluidCrystal® technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS